1. Αρχική σελίδα
  2. Αναζήτηση

Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia

Το τεκμήριο παρέχεται από τον φορέα :
Εθνικό Μετσόβιο Πολυτεχνείο   

Αποθετήριο :
Ψηφιακό Αποθετήριο της Κεντρικής Βιβλιοθήκης του ΕΜΠ | Dspace@NTUA   

δείτε την πρωτότυπη σελίδα τεκμηρίου
στον ιστότοπο του αποθετηρίου του φορέα για περισσότερες πληροφορίες και για να δείτε όλα τα ψηφιακά αρχεία του τεκμηρίου*



Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia (EN)
Stavroyianni, N (EN)
Skandali, A (EN)
Viniou, N (EN)
Marinakis, T (EN)
Yataganas, X (EN)
Tsimberidou, AM (EN)
Sakellari, L (EN)
Tiniakou, M (EN)
Papaioannou, M (EN)
journalArticle (EN)
2014-03-01T01:53:06Z
2003 (EN)
BACKGROUND. Postremission therapy is critical in maintaining complete remission (CR) in patients with de novo acute myelogenous leukemia (AML). The aim of this trial was to compare allogeneic stem cell transplantation (SCT), high-dose cytarabine (ara-C; HiDAC), and autologous SCT as postremission therapy in patients with de novo AML. METHODS. One hundred twenty patients age less than or equal to 60 years with previously untreated AML (non-M3) and a performance status score of less than or equal to 2 received induction therapy with 3 days of idambicin and 7 days of ara-C (IA). Patients in CR received one course of HiDAC. Subsequently, patients age ! 50 years with available HLA-compatible donors were assigned to receive allogeneic SCT; patients with "favorable" cytogenetics received a second course of HiDAC; and all others were randomized to a second course of HiDAC or autologous SCT. RESULTS. The IA combination induced CR in 99 patients (82.5%). With a median follow-up of 43 months (range, 18-64 years), the 3-year survival and failure-free survival (FFS) rates were 47% and 45%, respectively. The factors associated with longer survival were those identified for CR (i.e., age and cvtogenetics). Forty-nine patients (49%) received the assigned postremission therapy. Fifteen patients underwent allogeneic SCT. Nineteen patients underwent autologous SCT and 15 patients received a second course of HiDAC, after randomization. In the allogeneic SCT group, both the 3-year survival and the FFS rates were 73%. In the autologous SCT and HiDAC groups, the 3-year survival rates were 58% and 46%, respectively (P = 0.80), and the 3-year FFS rates were 42% and 33%, respectively (P = 0.83). CONCLUSIONS. The three postremission treatment groups had comparable survival. Allogeneic SCT is associated with a prolonged FFS. (EN)
Oncology (EN)
MAINTENANCE CHEMOTHERAPY (EN)
ACUTE NONLYMPHOCYTIC LEUKEMIA (EN)
INTENSIVE CONSOLIDATION CHEMOTHERAPY (EN)
autologous stem cell transplantation (EN)
ACUTE MYELOCYTIC-LEUKEMIA (EN)
ACUTE MYELOID-LEUKEMIA (EN)
MRC AML-10 TRIAL (EN)
PHASE-III TRIAL (EN)
de novo acute myelogenous leukemia (AML) (EN)
allogeneic stem cell transplantation (EN)
BONE-MARROW TRANSPLANTATION (EN)
CANCER STUDY-GROUP (EN)
postremission therapy (EN)
FIRST COMPLETE REMISSION (EN)
high-dose chemotherapy (EN)
CANCER (EN)
Αγγλική γλώσσα
JOHN WILEY & SONS INC (EN)
Εθνικό Μετσόβιο Πολυτεχνείο
Ψηφιακό Αποθετήριο της Κεντρικής Βιβλιοθήκης του ΕΜΠ | Dspace@NTUA
Κεντρική Βιβλιοθήκη Ε.Μ.Π.
Ιδρυματικό Αποθετήριο
Δημοσιεύσεις μελών Δ.Ε.Π. σε περιοδικά



*Η εύρυθμη και αδιάλειπτη λειτουργία των διαδικτυακών διευθύνσεων των συλλογών (ψηφιακό αρχείο, καρτέλα τεκμηρίου στο αποθετήριο) είναι αποκλειστική ευθύνη των αντίστοιχων Φορέων περιεχομένου.